Aggregation System Improves Analysis of Sub-Visible Particles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aggregation System Improves Analysis of Sub-Visible Particles


Pharmaceutical Technology
Volume 38, Issue 5, pp. 2

Shimadzu Scientific Instrument’s Aggregates Sizer Aggregation Analysis System, provides real-time quantitative evaluation of 100 nm to 10 μm subvisible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early-stage drug development, manufacturers can save time and reduce costs. The Aggregates Sizer is capable of identifying SVP particles from invisible to visible in a single measurement in microsample quantities as small as 0.4 mL. It also enables quantitative evaluation of the concentration of those aggregates. In addition, the Aggregates Sizer can execute ongoing measurements in intervals as short as one second, allowing users to evaluate rates of change at intermediate stages during the manufacturing process. A batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated.

Shimadzu Scientific Instruments

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here